Abstract: An article having: an elastomeric jacket; a gel within the jacket; and a plurality of gas-filled, polymerically-encapsulated microbubbles suspended in the gel. The microbubbles have a Gaussian particle size distribution. The largest microbubble has a diameter at least 10 times the diameter of the smallest microbubble. The article may exhibit Anderson localization at at least one frequency of sound waves impacting the article.

Abstract: A computer system displays a first version of a first user interface that includes first user interface objects displayed concurrently with a first background. The first user interface objects include content from a first plurality of applications. In response to detecting a first input, when the first input includes movement in a first direction, the system replaces display of the first version of the first user interface with a second user interface that includes representations of a second plurality of applications. When the first input includes second movement in a second direction, the system replaces display of the first version of the first user interface with display of a second version of the first user interface that includes second user interface objects displayed with a second background. The second user interface objects correspond to a third plurality of applications and include content from the third plurality of applications.

Abstract: In accordance with some embodiments, a method is performed at a device with one or more processors, non-transitory memory, a display, and an input device. The method includes displaying, on the display, a playback status indicator regarding playback of a media item. The method includes displaying, on the display, an image associated with the media item. The method includes detecting an input interacting with the image. In response to a first portion of the input, the method includes adjusting the appearance of the image on the display in accordance with the first portion of the input. In response to a second portion of the input, the method includes changing playback of media items on the device in accordance with the input in accordance with the second portion of the input.

Abstract: Polyurethanes are made in a one-shot process from one or more polyols having a hydroxyl equivalent weight of at least 350, wherein at least 50% of the weight of iii) is a hydroxyl-containing polymer of propylene oxide, the hydroxyl-containing polymer of propylene oxide having a hydroxyl equivalent weight of at least 350, an average of 1.8 to 3 hydroxyl groups per molecule of which hydroxyl groups 40 to 70% are primary hydroxyl groups, an oxyethylene content of no greater than 10% by weight based on the weight of the polymer and a polydispersity of 1.175 or less. The polyurethanes exhibit excellent mechanical properties, are highly hygroscopic and cured rapidly.

Abstract: A stent for treating a physical anomaly. The stent includes a skeletal support structure for expanding in the physical anomaly and a shape memory material coupled to the skeletal support structure.

Abstract: Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with TREX1.

Abstract: A method and apparatus for producing product packages comprises operating first and second feedback control loops where product package weight is averaged and used to determine one of two possible adjustments to change the product fill rate and the volume of the product. The feedback loops operate in one of a plurality of index levels. The first feedback loop seeks to improve performance by making adjustments to the fill rate and volume of the product, while incrementally moving to more stable index levels requiring tighter tolerances and package weight averages based on more product packages. The second feedback loop seeks to preserve stability by making its own adjustments to the fill rate and volume of the product if large product package weight fluctuations are sensed. The second feedback loop can move operation to less stable index levels having wider tolerances and package weight averages based on fewer product packages.

Abstract: A method and apparatus for producing product packages comprises operating first and second feedback control loops where product package weight is averaged and used to determine one of two possible adjustments to change the product fill rate and the volume of the product. The feedback loops operate in one of a plurality of index levels. The first feedback loop seeks to improve performance by making adjustments to the fill rate and volume of the product, while incrementally moving to more stable index levels requiring tighter tolerances and package weight averages based on more product packages. The second feedback loop seeks to preserve stability by making its own adjustments to the fill rate and volume of the product if large product package weight fluctuations are sensed. The second feedback loop can move operation to less stable index levels having wider tolerances and package weight averages based on fewer product packages.

Abstract: Systems and methods are described herein that provide user(s) with a customized landing page that is based on a location (e.g., a business or organization) at which the user is located. The customized landing page may be configured to enable a consumer to access the Internet via an Internet hotspot provided by the business or organization. The customized landing page may require the consumer(s) to perform certain actions before enabling a consumer to access the Internet. Such actions include, but are not limited to, viewing advertisements, providing demographic information and/or contact information, and/or interacting with one or more services. Upon connecting to the Internet, various performance indicators associated with the consumer(s) may be determined. An administrator of a hotspot provider may be enabled to view the performance indicator(s) and market themselves accordingly.

Abstract: Systems and methods are described herein that provide user(s) with a customized landing page that is based on a location (e.g., a business or organization) at which the user is located. The customized landing page may be configured to enable a consumer to access the Internet via an Internet hotspot provided by the business or organization. The customized landing page may require the consumer(s) to perform certain actions before enabling a consumer to access the Internet. Such actions include, but are not limited to, viewing advertisements, providing demographic information and/or contact information, and/or interacting with one or more services. Upon connecting to the Internet, various performance indicators associated with the consumer(s) may be determined An administrator of a hotspot provider may be enabled to view the performance indicator(s) and market themselves accordingly.

Abstract: The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and vinca alkaloids, which have anti-tumour activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and vincristine. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods of preparing the combinations of the invention.

Abstract: The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and an alkylating agent, which has anti-tumour activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and cyclophosphamide. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods of preparing the combinations of the invention.

Abstract: The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors, which have anti-tumour activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from carboplatin, gemcitabine, cisplatin, 5-fluorouracil, cyclophosphamide, etoposide, vincristine, doxorubicin and irinotecan. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods of preparing the combinations of the invention.

Abstract: The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a platinum compound which has anti-tumour activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and carboplatin. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods of preparing the combinations of the invention.

Abstract: The present invention relates to synergistic combinations of the compound 5, 6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from anthracyclines and topisomerase II inhibitors, which have anti-tumor activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from etoposide, and doxorubicin. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods of preparing the combinations of the invention.

Abstract: The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors, which have anti-tumour activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from carboplatin, gemcitabine, cisplatin, 5-fluorouracil, cyclophosphamide, etoposide, vincristine, doxorubicin and irinotecan. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods of preparing the combinations of the invention.

Abstract: This invention relates to a method of treating cancer, and particularly a method including the steps of administering to a mammal in need of such treatment, either simultaneously or sequentially, (i) a compound selected from a paclitaxel and docetaxel, and (ii) a compound of the formula or a pharmaceutically acceptable salt or ester thereof; wherein R1, R2 and R3 are each independently selected from the group consisting of H, C1-C6 alkyl, halogen, CF3, CN, NO2, NH2, OH, OR, NHCOR, NHSO2R, SR, SO2R or NHR, wherein each R is independently C1-C6 alkyl optionally substituted with one or more substituents selected from hydroxy, amino and methoxy, and wherein each of R1, R2 and R3 may be present at any of the available positions 1 to 8; and wherein in each of the carbocyclic aromatic rings in formula (I), up to two of the methine (—CH═) groups may be replaced by an aza (—N═) group; and wherein any two of R1, R2 and R3 may additionally together represent the group —CH

Abstract: This invention relates to a method of treating cancer, and particularly a method including the steps of administering to a mammal in need of such treatment, either simultaneously or sequentially, (i) a compound selected from a paclitaxel and docetaxel, and (ii) a compound of the formula 1

Abstract: A method of treating neoplastic disease wherein a patient in need of such treatment is administered an effective amount of a radiation-activated cytotoxin prodrug (RACP) which has low toxicity, which is reducible by reducing agents generated by the radiolysis of water and which, upon reduction, releases a sufficient amount of a cytotoxic effector of sufficient cytotoxic potency to kill tumor cells. The tumor cells are irradiated with ionizing radiation to reduce the prodrug which is present at the locus of the tumor cells to release the cytotoxic effector.